Back to Search
Start Over
Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema
- Source :
- JAMA Ophthalmology. 136:382
- Publication Year :
- 2018
- Publisher :
- American Medical Association (AMA), 2018.
-
Abstract
- IMPORTANCE: Variability in response to anti–vascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME) remains a significant clinical challenge. Biomarkers could help anticipate responses to anti-VEGF therapy. OBJECTIVES: To investigate aqueous humor cytokine level changes in response to intravitreal ranibizumab therapy for the management of DME, and to determine the association between baseline aqueous levels and anatomic response. DESIGN, SETTING, AND PARTICIPANTS: In this prospective multicenter cohort study, 49 participants with diabetes mellitus complicated by center-involving DME, with a central subfield thickness of 310 μm or greater on spectral-domain optical coherence tomography (SD-OCT), were recruited from December 22, 2011, to June 13, 2013 and statistical analysis were performed from March 1, 2017, to June 1, 2017. A total of 48 participants proceeded to follow-up. INTERVENTIONS: Participants received monthly injections of ranibizumab, 0.5 mg, for 3 months. Aqueous fluid for cytokine analysis was obtained at baseline and repeated at the 2-month visit. Multiplex immunoassay was carried out in duplicate for VEGF, placental growth factor, transforming growth factor beta 2, intercellular adhesion molecule 1 (ICAM-1), interleukin 6 (IL-6), IL-8, IL-10, vascular intercellular adhesion molecule, and monocyte chemoattractant protein 1. MAIN OUTCOMES AND MEASURES: Baseline and 2-month change in aqueous cytokine levels, 3-month change in SD-OCT central subfield thickness and macular volume (MV), and the statistical association between baseline aqueous cytokine levels and these measures of anatomic response to ranibizumab in center-involving DME. RESULTS: Among the 48 participants, the mean (SD) age was 61.9 (7.1) years and 36 participants (75.0%) were men. The following cytokines were lower at month 2 vs baseline: ICAM-1 (median change, −190.88; interquartile range [IQR], −634.20 to −26.54; P
- Subjects :
- Male
Vascular Endothelial Growth Factor A
0301 basic medicine
Time Factors
Visual acuity
genetic structures
Visual Acuity
Angiogenesis Inhibitors
0302 clinical medicine
Interquartile range
Macula Lutea
Prospective Studies
Prospective cohort study
Original Investigation
biology
Middle Aged
Treatment Outcome
Intravitreal Injections
Cytokines
Female
medicine.symptom
Tomography, Optical Coherence
Retinopathy
medicine.drug
Adult
medicine.medical_specialty
Drug Administration Schedule
Macular Edema
Aqueous Humor
03 medical and health sciences
Ranibizumab
Ophthalmology
Diabetes mellitus
medicine
Humans
Interleukin 6
Aged
Diabetic Retinopathy
Dose-Response Relationship, Drug
business.industry
Odds ratio
medicine.disease
030104 developmental biology
030221 ophthalmology & optometry
biology.protein
business
Biomarkers
Follow-Up Studies
Subjects
Details
- ISSN :
- 21686165
- Volume :
- 136
- Database :
- OpenAIRE
- Journal :
- JAMA Ophthalmology
- Accession number :
- edsair.doi.dedup.....0c73ce76b743e9c4fb1daa1583cffa80
- Full Text :
- https://doi.org/10.1001/jamaophthalmol.2018.0179